Key Inclusion Criteria*

        Criteria for NHL:

          -  r/r B-cell NHL that is histologically confirmed by archived tumor biopsy tissue from
             the last relapse and corresponding pathology report.

          -  Measurable or detectable disease according to the Lugano classification.

          -  Primary refractory disease or r/r disease after a response to 2 prior regimens.

        Criteria for CLL/SLL:

          -  Diagnosis of CLL with indication for treatment based on the iwCLL guidelines and
             clinically measurable disease or SLL with measurable disease that is biopsy-proven
             SLL.

          -  Previously failed/tolerant to at least 2 prior lines of systemic targeted therapy of
             known benefit.

        Criteria for both NHL and CLL/SLL:

          -  Study participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status
             score of 0 or 1.

          -  Study participant has adequate bone marrow, renal, hepatic, pulmonary, and cardiac
             function.

        Key Exclusion Criteria*:

        Criteria for NHL:

          -  Requirement for urgent therapy due to mass effects such as bowel obstruction, spinal
             cord, or blood vessel compression.

          -  Active central nervous system (CNS) disease. A negative computed tomography
             (CT)/magnetic resonance imaging (MRI) is required at Screening if the study
             participant has a history of CNS lymphoma.

        Criteria for CLL/SLL:

          -  Active CNS disease. A negative lumbar puncture is required at Screening if the study
             participant has a history of CNS disease.

        Criteria for NHL and CLL/SLL:

          -  Previous malignancy, besides the malignancies of inclusion (B-cell NHL or CLL/SLL),
             that in the investigator's opinion, has a high risk of relapse in the next 2 years.

          -  Active uncontrolled fungal, bacterial, viral, protozoal, or other infection.

          -  Any form of primary immunodeficiency.

          -  History of human immunodeficiency virus (HIV) infection.

          -  Active hepatitis B or C.

          -  Uncontrolled cardiovascular disease.

          -  Hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening.

          -  Presence of a CNS disorder that renders ineligible for treatment.

          -  History of a genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman
             Diamond syndrome, or any other known bone marrow failure syndrome.

          -  Active hemolytic anemia.

          -  Received ASCT within 45 days of Screening if the study participant has met the rest of
             the count requirements.

          -  Must not have received systemic corticosteroid therapy for at least 1 day prior to
             initiating lymphodepletion chemotherapy.

          -  Received a systemic biologic agent within 30 days or 5 half-lives.

          -  Received a live vaccine within 4 weeks before Screening.

          -  Received standard cytotoxic chemotherapy within 10 days of Screening.

          -  Radiotherapy within 4 weeks determined on a case-by-case basis.

          -  Presence of a pleural/peritoneal/pericardial catheter.

          -  Current use of any anticoagulant or antiplatelet therapy.

               -  Additional criteria apply